No abstract

No abstract

Aims of study: This study compares changes in lipid profile and carotid intima-media thickness and their use as surrogate biomarkers, after treatment with atorvastatin and rosuvastatin given to hypercholesterolemia patients. Methodology:Lipid profile was done after overnight fasting in patients with history of hypercholesterolemia or family history of premature coronary artery diseases. B-mode ultrasonography was done to measure mean carotid intima-media thickness on a Toshiba (M# SSA-580A/E2) ultrasound scanner with linear probe. Both treatment groups, one on atorvastatin (20 mg) and other on rosuvastatin (10 mg) were followed-up for two years. Results:Total of forty two patients of heterozygous familial hypercholesterolemia were followed -up for two years. Total cholesterol reduction was (45%) and LDL-cholesterol (48%) in patients on rosuvastatin 10 mg/day, as compared to total cholesterol reduction (36%) and LDL-cholesterol (37%) in patients on atorvastatin 20 mg/day (**p < 0.001). The mean CIMT regression in both treatment groups was significant (0.11 mm) in rosuvastatin treatment group and (0.08 mm) in atorvastatin treatment group (*p < 0.02). Conclusion:This study has shown better efficacy of rosuvastatin as compared to atorvastatin in reduction of LDLcholesterol and carotid -intima media thickness.

Benign prostatic hyperplasia is the most common prostatic pathology and its incidence has accelerated recently [1]. Benign prostatic hyperplasia (BPH) is diagnosed histologically as enlargement of mucosal and sub mucosal glands with the proliferation of prostatic stroma occurring within the prostatic transition zone [2]. BPH compresses the urethra resulting in anatomic benign prostatic obstruction and may present as lower urinary tract symptoms (LUTS). The prevalence of LUTS can be progressive in the aging male [3]. LUTS associated with BPH usually affects 45% of males in their 50s, and 80% of males are affected by LUTS in their 70s [4]. Benign Prostatic Hyperplasia is not a life threatening condition, but has negative impact on a patient's quality of life as evidenced in community and clinical studies [5]. Obstruction related LUTS that develops in BPH occurs as a result of dynamic and static components [6]. In order to evaluate the BPH\LUTS American Urology Association devised a scoring system called AUASI (American Urological Association Symptom Index) which consists of six questions and International Prostate Review ArticleSymptom Score (IPSS) is based on seven questions and their answers concerning urinary symptoms [7]. Data Selection: Literature published during 2008-2014 were selected for review from crosssectional and cohort studies. Data Extraction: Data was collected and assembled from NCBI, Google Scholar, journals of Radiology and Urology. Conclusion:The accurate assessment of LUTS plays a pivotal role in the interpretation of benign prostatic hyperplasia therefore, the authenticity of symptom scores is crucially important. International prostatic symptom score is the paradigm questionnaire for subjective evaluation of symptoms of the lower urinary tract [8]. The IPSS and IPSS quality of life (QoL) questionnaire can be an important tool for the diagnosis of BPH.